GFAP Antikörper (N-Term)

Produktnummer ABIN357395

Der Kaninchen Polyklonal Anti-GFAP-Antikörper wurde für WB, IHC (p) und EIA validiert. Er ist geeignet, GFAP in Proben von Human zu detektieren. Es sind 4+ Publikationen verfügbar.

Kurzübersicht für GFAP Antikörper (N-Term) (ABIN357395)

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser GFAP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-GFAP Antikörper

Bindungsspezifität: N-Term

Spezifität: This antibody detects GFAP N-term.

Aufreinigung: Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS

Immunogen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human GFAP.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Immunohistochemistry 1: 50 - 1: 100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody at 2 - 8 °C up to one month or (in aliquots) at -20 °C for longer.

Referenzen für anti-GFAP Antikörper (ABIN357395)

Curtis, Martin, Gabel, Sidhu, Rzesiewicz, Mandeville, Van Gorp, Leerink, Tadokoro, Marsala, Jamieson, Marsala, Ciacci: "A First-in-Human, Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury." in: Cell stem cell, Vol. 22, Issue 6, pp. 941-950.e6, (2018) (PubMed).

Kadoya, Lu, Nguyen, Lee-Kubli, Kumamaru, Yao, Knackert, Poplawski, Dulin, Strobl, Takashima, Biane, Conner, Zhang, Tuszynski: "Spinal cord reconstitution with homologous neural grafts enables robust corticospinal regeneration." in: Nature medicine, Vol. 22, Issue 5, pp. 479-87, (2017) (PubMed).

Lu, Ceto, Wang, Graham, Wu, Kumamaru, Staufenberg, Tuszynski: "Prolonged human neural stem cell maturation supports recovery in injured rodent CNS." in: The Journal of clinical investigation, Vol. 127, Issue 9, pp. 3287-3299, (2017) (PubMed).

Miyanohara, Kamizato, Juhas, Juhasova, Navarro, Marsala, Lukacova, Hruska-Plochan, Curtis, Gabel, Ciacci, Ahrens, Kaspar, Cleveland, Marsala: "Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs." in: Molecular therapy. Methods & clinical development, Vol. 3, pp. 16046, (2016) (PubMed).

Details zu GFAP

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Andere Bezeichnung: GFAP

Hintergrund: GFAP is one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system.Synonyms: Glial Fibrillary Acidic Protein

Molekulargewicht: 49880 Da

Gen-ID: 2670

NCBI Accession: NP_001124491

UniProt: P14136